Literature DB >> 31570933

The Current Status of Devices for the Treatment of Resistant Hypertension.

Michael Kunz1, Lucas Lauder1, Sebastian Ewen1, Michael Böhm1, Felix Mahfoud1,2.   

Abstract

Arterial hypertension is associated with increased cardiovascular morbidity and mortality. Although blood pressure-lowering therapies significantly reduce the risk of major cardiovascular events, blood pressure control remains unsatisfactorily low. Several device-based antihypertensive therapies have been investigated in patients with treatment-resistant hypertension and in patients unable or unwilling to adhere to antihypertensive medication. As the field of device-based therapies is subject to constant change, this review aims at providing an up-to-date overview of different device-based approaches for the treatment of hypertension. These approaches target the sympathetic nervous system (renal denervation, baroreflex amplification therapy, baroreflex activation therapy, and carotid body ablation) or alter mechanical arterial properties by creating an iliac arteriovenous fistula. Notably, the use of all of these treatment options is not recommended for the routine treatment of hypertension by current guidelines but should be investigated in the context of controlled clinical studies. © American Journal of Hypertension, Ltd 2019. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  baroreflex activation therapy; baroreflex amplification therapy; blood pressure; carotid body ablation; device-based therapy; hypertension; renal denervation; resistant hypertension

Mesh:

Year:  2020        PMID: 31570933     DOI: 10.1093/ajh/hpz161

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  1 in total

1.  Socioeconomic differentials in trends in the prevalence of hypertension and pre-hypertension and hypertension awareness, treatment, and control in rural Southwestern China.

Authors:  Lu-Ming Fan; Fang Wang; Min Zhao; Wen-Long Cui; Le Cai
Journal:  BMC Cardiovasc Disord       Date:  2021-05-26       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.